Vertex Pharmaceuticals, Inc. (VRTX)
547.61
+3.09
(+0.57%)
USD |
NASDAQ |
Sep 01, 16:00
547.66
+0.05
(+0.01%)
After-Hours: 18:13
Vertex Pharmaceuticals Cash from Investing (Quarterly) : -45.80M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -45.80M |
| March 31, 2026 | -431.90M |
| December 31, 2025 | -288.10M |
| September 30, 2025 | -117.00M |
| June 30, 2025 | -484.50M |
| March 31, 2025 | -55.80M |
| December 31, 2024 | -821.90M |
| September 30, 2024 | -348.00M |
| June 30, 2024 | -463.70M |
| March 31, 2024 | -2.136B |
| December 31, 2023 | -886.50M |
| September 30, 2023 | -117.70M |
| June 30, 2023 | -303.90M |
| March 31, 2023 | -1.834B |
| December 31, 2022 | 175.60M |
| September 30, 2022 | -384.20M |
| June 30, 2022 | -61.50M |
| March 31, 2022 | -51.00M |
| December 31, 2021 | -134.00M |
| September 30, 2021 | -52.95M |
| June 30, 2021 | -79.64M |
| March 31, 2021 | -74.31M |
| December 31, 2020 | 243.75M |
| September 30, 2020 | -247.94M |
| June 30, 2020 | 71.91M |
| Date | Value |
|---|---|
| March 31, 2020 | 31.67M |
| December 31, 2019 | -896.99M |
| September 30, 2019 | -249.00M |
| June 30, 2019 | -50.19M |
| March 31, 2019 | -39.14M |
| December 31, 2018 | -33.01M |
| September 30, 2018 | -49.89M |
| June 30, 2018 | -116.30M |
| March 31, 2018 | 4.933M |
| December 31, 2017 | -21.41M |
| September 30, 2017 | -163.68M |
| June 30, 2017 | -76.28M |
| March 31, 2017 | -160.98M |
| December 31, 2016 | 219.51M |
| September 30, 2016 | 22.70M |
| June 30, 2016 | -63.54M |
| March 31, 2016 | -105.34M |
| December 31, 2015 | -122.69M |
| September 30, 2015 | -100.94M |
| June 30, 2015 | 278.44M |
| March 31, 2015 | 214.04M |
| December 31, 2014 | -27.70M |
| September 30, 2014 | 30.54M |
| June 30, 2014 | 89.88M |
| March 31, 2014 | -20.41M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Gilead Sciences, Inc. | -10.35B |
| Alnylam Pharmaceuticals, Inc. | -363.46M |
| Sionna Therapeutics, Inc. | 21.47M |
| Regeneron Pharmaceuticals, Inc. | -92.70M |
| Biogen, Inc. | -3.839B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 1.125B |
| Cash from Financing (Quarterly) | -426.70M |
| Free Cash Flow | 3.796B |
| Free Cash Flow Per Share (Quarterly) | 3.970 |
| Free Cash Flow to Equity (Quarterly) | 1.022B |
| Free Cash Flow to Firm (Quarterly) | 1.013B |
| Free Cash Flow Yield | 2.70% |